You are here
ALLELE BIOTECHNOLOGY AND PHARMACEUTICALS
UEI: N/A
# of Employees: 0
HUBZone Owned: No
Socially and Economically Disadvantaged: Yes
Woman Owned: No
Award Charts
Award Listing
-
Effective Nanoantibodies as Promising Therapeutics for Treating Sepsis
Amount: $225,001.00PROJECT SUMMARYABSTRACTThe innate immune system releases multiple inflammatory cytokines in response to pathogens and their toxins to combat infectionSepsis and septic shock develop when such inflamma ...
SBIRPhase I2018Department of Health and Human Services National Institutes of Health -
Human Neural Stem Cells Engineered against oAβ Induced Toxicity for Cell Therapy
Amount: $225,000.00Project Summary Abstract The goal of this project is to develop a tissue engineering technology applicable to stem cell based therapies for Alzheimerandapos s disease AD AD is the most common demen ...
SBIRPhase I2017Department of Health and Human Services National Institutes of Health -
Anti-RPS23RG1 Nanoantibody as Novel Therapeutic and Research Reagents for Alzheimer’s Disease.
Amount: $225,000.00Abstract Alzheimerandapos s disease AD is the most common dementia in the elderly Currently there is no cure for the disease Pathologically AD is characterized by the presence of extracellular ...
SBIRPhase I2016Department of Health and Human Services National Institutes of Health -
Adaptable and Automated Large-Scale Manufacturing of iPSC-Derived Cell Products
Amount: $222,173.00Summary Statement and Abstract Stem cell technology is revolutionizing regenerative medicine and cell based therapies One of the promising applications of this technology is stem cell derived platele ...
SBIRPhase I2016Department of Health and Human Services National Institutes of Health -
Generation and Characterization of Nanobodies Against beta-Amyloid
Amount: $224,999.00DESCRIPTION provided by applicant Alzheimerandapos s disease AD is the most common dementia in the elderly and imposes a tremendous burden to patientsandapos families and the society both financ ...
SBIRPhase I2015Department of Health and Human Services National Institutes of Health -
Nano-Antibodies for Studying RNA Modifications
Amount: $225,000.00DESCRIPTION (provided by applicant): The goal of the proposed Phase I research is to develop a set of commercial reagents for recognizing 2'-O-methyladenosine (Am), 2'-O-methylcytidine (Cm), ...
SBIRPhase I2014Department of Health and Human Services National Institutes of Health -
RNA-Guided Gene Targeting in Human Cells
Amount: $153,057.00Project Summary/Abstract The goal of the proposed Phase I research is to develop a set of commercial kits for footprint-free genome engineering. The core technologies that serve as the foundation of t ...
SBIRPhase I2014Department of Health and Human Services National Institutes of Health -
Improving Pediatric Developmental Screening and Communication: A CME
Amount: $199,939.00DESCRIPTION (provided by applicant): The goal of the proposed project is to develop a commercial kit that will allow drug addiction researchers with ongoing projects using cell-based models to be able ...
SBIRPhase I2013Department of Health and Human Services National Institutes of Health -
TAS::75 0893::TAS SINGLE CHAIN ANTIBODIES AS RENEWABLE CAPTURE REAGENTS
Amount: $200,000.00The main objective of this contract is to generate VHH antibodies against 10 addiction-relevant proteins. Protocols will be established for efficiently identifying single chain VHH antibodies from lla ...
SBIRPhase I2011Department of Health and Human Services National Institutes of Health -
RNA Resource for Synthetic Lethal Screening of DNA Repair and
Amount: $199,918.00The objectives of this proposal are to develop gene silencing reagents, and to test/validate their use in synthetic lethal screening of DNA damage signaling and repair pathways. Making such reagents ...
SBIRPhase I2010Department of Health and Human Services National Institutes of Health